|
|
|
Volumn 13, Issue 3, 2010, Pages 142-144
|
|
28th annual JPMorgan healthcare conference - Affymax and infinity pharmaceuticals
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
ANTINEOPLASTIC AGENT;
CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR;
ERYTHROPOIETIN;
FATTY ACID AMIDASE INHIBITOR;
GEMCITABINE;
HEAT SHOCK PROTEIN 90;
IPI 493;
IPI 926;
IPI 940;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
RETASPIMYCIN;
TANESPIMYCIN HYDROQUINONE;
UNCLASSIFIED DRUG;
ANEMIA;
ANXIETY DISORDER;
ARTERIOVENOUS FISTULA THROMBOSIS;
BREAST CANCER;
CANCER THERAPY;
CLINICAL TRIAL;
CONFERENCE PAPER;
DEPRESSION;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG STRUCTURE;
DRUG TOLERABILITY;
HEALTH CARE;
HUMAN;
HYPERTENSION;
INFLAMMATION;
LUNG NON SMALL CELL CANCER;
MALIGNANT NEOPLASTIC DISEASE;
MEDICAL LITERATURE;
MEDULLOBLASTOMA;
NEUROPATHIC PAIN;
NONHUMAN;
OSTEOARTHROPATHY;
PANCREAS CANCER;
PURE RED CELL ANEMIA;
SOLID TUMOR;
UNITED STATES;
UNSPECIFIED SIDE EFFECT;
AMIDOHYDROLASES;
ANALGESICS;
ANEMIA;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG INDUSTRY;
DRUGS, INVESTIGATIONAL;
ENZYME INHIBITORS;
HEDGEHOG PROTEINS;
HEMATINICS;
HUMANS;
PEPTIDES;
POLYETHYLENE GLYCOLS;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
|
|
EID: 77749292476
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
